



## **Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes**

**LSE Research Online URL for this paper:** <http://eprints.lse.ac.uk/106620/>

Version: Accepted Version

---

### **Article:**

Bauer, Annette ORCID: 0000-0001-5156-1631, Wittenberg, Raphael ORCID: 0000-0003-3096-2721, Ly, Amanda, Gustavsson, Anders, Bexelius, Christin, Tochel, Claire, Knapp, Martin ORCID: 0000-0003-1427-0215, Nelson, Mia and Sudlow, Catherine (2020) Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes. *International Journal of Technology Assessment in Health Care*, 36 (4). 297 - 303. ISSN 0266-4623

<https://doi.org/10.1017/S0266462320000574>

---

### **Reuse**

Items deposited in LSE Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the LSE Research Online record for the item.

Table 1: Features of health technology assessment (HTA) agencies in England, Germany, and The Netherlands

<b>COUNTRY</b>	<b>ENGLAND</b>	<b>GERMANY</b>	<b>NETHERLANDS</b>
<b>HTA Agency's name</b>	<b>National Institute for Health and Care Excellence (NICE)</b>	<b>Institute for Quality and Efficiency in Health Care (IQWiG)</b>	<b>Zorginstituut Netherlands (ZIN)</b>
Roles & responsibilities	Advice about which drugs get funded based on cost-effectiveness (=fourth hurdle)	Advice on added value used to inform price negotiations	Advice informs whether drug gets on positive list (which influences price)
Value assessment	Cost-effectiveness	Clinical benefit	Clinical benefit; cost-effectiveness for drugs above certain threshold
Enforcement of methods	Guidance (manual) and reference case	Legislation and guidance	Guidance and reference case
Stakeholder involvement	Public consultations, Committee of experts (including patient representatives) co-develops guideline	Consultation with experts (including patient representatives)	Consultation with experts (including patient representatives)